Invitation to Enefit Green investor webinars presenting Q1 2025 interim results

5 hours ago

Enefit Green will publish its Q1 2025 interim report on 08 May 2025 at 09.00 EEST and will host two webinars…

Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy

5 hours ago

Angelini Ventures marks its first investment in the cardiovascular and gene therapy space – and first in Asia, further diversifying…

Inbank unaudited financial results for Q1 2025

5 hours ago

In Q1 2025 Inbank earned a consolidated net profit of 4.5 million euros, increasing 14% year-on-year. The return on equity…

International Petroleum Corporation Announces First Quarter 2025 Financial and Operational Results

5 hours ago

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operational results and related…

Report for the three months ended 31 March 2025

5 hours ago

Highlights Power generation amounted to 251 GWh for the first quarter 2025, being at the lower end of the outlook…

Q1 2025 INTERIM REPORT – 2025-TRANSITION PROGRESSING

5 hours ago

Announcement no. 19 - 6 May 2025 Q1 2025 Revenue up 8% to DKK 7.5bn. Organic growth was -1%EBIT reduced…

Three-month interim report (Q1) 2025 (unaudited)

5 hours ago

ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue…

International Petroleum Corporation Announces First Quarter 2025 Financial and Operational Results

5 hours ago

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operational results and related…

Coloplast A/S – Announcement no. 04/2025 – Interim Financial Report, H1 2024/25

5 hours ago

Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted…

Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

6 hours ago

Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible…

This website uses cookies.